Investor's Business Daily on MSN
Novo Nordisk CFO On Metsera, Hims And Lilly, And Why 'Hyper Growth' Has Stalled
Novo Nordisk stock skidded early Wednesday after the Wegovy and Ozempic maker cut its sales outlook for the third time this ...
Welltica+ on MSN
Scientists investigate whether Ozempic could influence fertility
Scientists are investigating whether popular weight-loss drugs like Ozempic could influence fertility or interfere with birth ...
The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...
Opinion
4hOpinion
Opinion | The Rich Get Fit, And Poor Get 'Lectures' - That's India's Ozempic Problem
The rise of a grey market in India, where unsupervised doses are sold at exorbitant rates, demonstrates that excessive control merely drives patients underground. Regulation should protect safety, not ...
Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.
Novo Nordisk CEO Maziar Mike Doustdar discusses demand for the Danish firm's weight-loss drug Wegovy and diabetes medication ...
Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback